Just in case
Vector has launched clinical trials of a smallpox vaccine
Irina Marakhovskaya, Naukograd-Press
Clinical trials of the first phase of the smallpox vaccine have begun in Russia. This was stated by Rinat Maksyutov, Director General of the Vector State Scientific Center for Virology and Biotechnology, at the II International Conference "Global Threats to Biological Security: problems and Solutions" in Sochi.
"The complex of preclinical trials of this vaccine on various animal models showed specific activity and safety, which allowed to start the first phase of clinical trials on 60 volunteers in May of this year. The aim is to study the safety, tolerability and immunogenicity of the fourth–generation anti-inflammatory vaccine for intradermal administration," he reported in the presence of experts from around the world.
The head of Rospotrebnadzor Anna Popova stressed during the conference that even considering that since 1977 the World Health Organization considers the disease eliminated, there remains a risk of its occurrence. "The population has stopped being vaccinated against smallpox since 1980. This creates high risks of temptation for the misuse of this pathogen, firstly - for non–peaceful purposes, and secondly - in case of its unexpected appearance. Therefore, there should be stocks of the vaccine. The pathogen is known, it is very dangerous, and we must have a means of protection against what we know about, even if it is not near us today," she said.
Portal "Eternal youth" http://vechnayamolodost.ru